Frontline PARP Inhibitor Shrinks Tumors in BRCA-Positive Breast Patients
Wednesday, October 5, 2016 - 09:31
in Health & Medicine
All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center.